Abstract PR009: DLL3 CAR-T and CAR-NK cell combination therapy promotes synergistic antitumor activity in small cell lung cancer

Alan E. Bers I. Gillanders Eden Bobilev C. Stornante Mubin Tarannum N. Mahadevan R. Romee M. Campisi D. Barbie

Jul 2026 · Clinical Cancer Research · Vol 32, pp. PR009-PR009 · 0 citations

TL;DR

The results suggest that DLL3-targeting CAR therapies represent a promising approach for treating SCLC, particularly given their ability to function independently of MHC-I, and a combination of CAR-T and CAR-NKs could be an efficacious approach to overcoming current limitations of CAR therapies in solid tumors.

Abstract

Small cell lung cancer (SCLC) is an aggressive form of lung cancer, with most patients showing poor response rates to immunotherapies, resulting in limited treatment options. Profiling of the SCLC TIME shows immunologic heterogeneity, with the majority of SCLC being neuroendocrine (NE) subtype and exhibiting low MHC-I expression, and a minority being non-neuroendocrine (non-NE) subtype, with higher MHC-I expression. Recent incorporation of T cell engagers targeting DLL3 and CD3 have shown promising results, however, MHC-I downregulation can potentially limit endogenous T cell activity and therapeutic responses. Chimeric antigen receptor (CAR) based therapies enable the genetic engineering of T or NK cells to target tumor-specific antigens independently of MHC-I, representing a promising therapeutic strategy for SCLC. However, CAR-NK cells’ proliferation and lifespan is limited compared to CAR-T cells. CAR-T might benefit from a combination with CAR-NK providing a rapid antitumor response to promote infiltration and expansion. In this study we aimed to use 3D micro-physiological systems to test whether a combination of CAR-T and CAR-NK could overcome CAR therapy limitations in solid tumors. DLL3 surface protein expression was characterized in SCLC cell lines by flow cytometry. Then, DLL3-targeting CAR-T and CAR-NK cells were generated through viral transduction and validated in both 2D and 3D tumor models. The combination of the CAR-T and CAR-NK was tested using a co-culture spheroids model in a 3D microfluidic device. Finally, infiltration of the CARs across a blood vessel barrier into the TME was investigated by creating a microphysiological system of SCLC TME. We found that DLL3 expression was heterogenous across SCLC cell lines, with NE SCLC exhibiting higher DLL3 expression than non-NE SCLC. Both DLL3 CAR-T and CAR-NK cells demonstrated potent antitumor activity in 2D and 3D culture, with CAR-NK cells showing more rapid cytotoxic activity compared to CAR-T cells, killing via antigen recognition but also recognizing the absence of MHC-I expression. We then sought to combine both therapies to investigate cooperative activity between the two effector-cell platforms. At a 6-day timepoint, without exogenous IL-2 stimulation, we found that the DLL3 CAR-T and CAR-NK cell combination showed the greatest anti-tumor activity in the DLL3+ NE cell lines, compared to either therapy alone when tested in the 3D microfluidic model, suggesting synergistic and bystander effector function. These results correlated with higher IL-2 and IFN-g production detected in conditioned media only in the CAR-T and CAR-NK cell combination treatment. These results suggest that DLL3-targeting CAR therapies represent a promising approach for treating SCLC, particularly given their ability to function independently of MHC-I. In addition, a combination of CAR-T and CAR-NKs could be an efficacious approach to overcoming current limitations of CAR therapies in solid tumors, including immune cell exclusion, persistence, and exhaustion. Alan E. Bers, Ian Gillanders, Eden Bobilev, Carla Stornante, Mubin Tarannum, Navin R. Mahadevan, Rizwan Romee, Marco Campisi, David A. Barbie. DLL3 CAR-T and CAR-NK cell combination therapy promotes synergistic antitumor activity in small cell lung cancer [abstract]. In: Proceedings of AACR Drug Discovery and Development (AACR D3) Conference; 2026 Jul 21-24; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(14_Suppl):Abstract nr PR009.

DOI Semantic Scholar

View source

Similar papers

Open access Jul 2026

T-bet CAR T cells: A new avenue for NSCLC therapy analyzed in lung cancer-derived organoids 2258880

Chimeric antigen receptor (CAR) T cell therapy in solid tumors is limited by the immunosuppressive tumor microenvironment (TME). Since we have identified T-bet as a strong anti-tumor candidate, we thought to explore new therapies against NSCLC by developing next-generation CAR T cells and patient-derived lung cancer organoids (PDOs) as a clinically relevant preclinical platform for evaluating CAR T cell antitumor efficacy. To explore strategies that improve CAR T cell efficacy and persistence, we first characterized T cells in the lung tumor environment by flow cytometry. Next, we cultured PBMCs and purified CD3+ T cells from patients with NSCLC with IL-2 or IL-2+ IL-12 to assess the changes in T-bet expression in vitro. We thus engineered B7-H3 (CD276) directed CAR T cells co-expressing either IL-12 or the transcription factor T-bet (TBX21). Simultaneously, patient-derived organoids were established from lung cancer tissues to preserve tumor heterogeneity and architecture as a clinically relevant platform for CAR T cell antitumor efficacy evaluation. Here we found low levels of Th1 T-bet + T cells in patients with NSCLC as compared to healthy controls. Moreover, in PBMCs under IL-2+ IL-12 stimulation, we found a significant expansion of CD3+CD4+ T-bet+ T cells. Preliminary data indicate that IL-12—armored CAR T cells exhibited the highest anti-tumor effect against the lung adenocarcinoma cell line A549, but raised concerns about systemic toxicity as confirmed in in vitro observations. In contrast, T-bet—modified CAR T cells displayed stronger CAR T cell survival and expansion associated with significant antitumor response. This study leverages PDOs as a clinically relevant preclinical model to optimize CAR T design and supports T-bet as a promising axis for developing safer and more durable next generation CAR T therapies against NSCLC. n/a Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)

Lin Li, D. Trufa, Bastian Zinkel et al. · Journal of Immunology · 0 citations

Open access Sep 2026

γδ T cells modulate anti-tumor immunity in small cell lung cancer.

Small cell lung cancer (SCLC) is a highly aggressive neoplasm with limited sensitivity to anti-PD-(L)1 blockade, which is likely caused by the epigenetic silencing of MHC-I. Elucidating MHC-I-independent immune recognition mechanisms is therefore crucial for enhancing treatment responses and improving clinical outcomes in a greater number of patients. Leveraging single-cell approaches, we discovered γδ T cell infiltration in biospecimens from patients with SCLC. Despite PD-1 expression, γδ T cells maintained a cytotoxic transcriptional profile, suggesting an anti-tumor role. Indeed, high γδ T cell infiltration in two practice-changing clinical trials predicted improved response to anti-PD-L1 immunotherapy in patients with SCLC. Moreover, using preclinical models, we demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate, an FDA-approved compound, can sensitize SCLC cells to γδ T cell-mediated killing. Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.

Jin Ng, Yue You, Tina Zhang et al. · Cancer Cell · 0 citations

Jul 2026

BCMA-CAR Natural Killer Cells Suppress Myeloma in Bone Marrow but Allow Emergence of Extramedullary Disease 2266680

This study showcases α-BCMA-CAR-IL15 NK cell therapy as a potent anti-MM therapeutic, achieving sustained MM elimination from the bone marrow and greatly extending survival in a MM-xenograft model, however, α-BCMA-CAR-IL15 NK cells appeared ineffective at eliminating extramedullary disease.

Seung-Hwan Lee, Shelby Kaczmarek, Safa Ghaziasgar et al. · Journal of Immunology · 0 citations

Open access Aug 2026

IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting

Chimeric antigen receptor (CAR) therapies have shown great success in hematological malignancies but remain largely ineffective against solid tumors such as pancreatic ductal adenocarcinoma (PDAC). A key obstacle among various aspects, is the dense stromal barrier formed by cancer-associated fibroblasts (CAFs), providing a rationale for simultaneously targeting stroma and tumor cells. Using immunohistochemistry of primary PDAC tumors and liver metastases, we confirmed high mesothelin (MSLN) expression on tumor cells, and CD70 expression on tumor cells and predominantly CAFs. Based on these results and the favorable safety profile of CAR natural killer (NK) cells over CAR T cells, we generated MSLN- and CD70-targeting IL-15-armored CAR NK cells. Both constructs mediated cytotoxicity against different pancreatic cancer and CAF cell lines with varying antigen expression in vitro, demonstrating that both, the CAR-molecule and IL-15 were required to increase functionality against more treatment-resistant cell lines. Interestingly, pooled MSLN- and CD70-CAR NK cells did not significantly improve cytolysis compared to monotherapies in an advanced 3D in vitro model or in vivo. Together these findings highlight the limitations of dual-targeting approaches and underscore the need for advanced engineering strategies to improve CAR NK cells beyond antigen targeting and cytokine support in the PDAC microenvironment.

Laura Gehrcken, J. Ott, Astrid Van Den Eynde et al. · Molecular therapy. Oncology · 0 citations

Aug 2026

Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC.

A humanized CD70-targeted CAR-T cell therapy is developed, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development.

Meng-Jia Zhang, Zhihao Wang, Cheng Gao et al. · International Immunopharmaco... · 0 citations

Aug 2026

P1.055. Combination of CAR-T Cell Therapy With Immune Checkpoint Inhibition Enhances Anti-Tumor Efficacy in Esophageal Squamous Cell Carcinoma

Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Chimeric antigen receptor (CAR)-T cell therapy has limited efficacy in solid tumors like esophageal squamous cell carcinoma (ESCC). This study investigates whether combining CAR-T cells with an anti-PD-1 antibody can overcome immunosuppression and improve therapeutic outcomes by remodeling the tumor microenvironment (TME). We constructed second-generation CAR-T cells targeting mesothelin, an antigen overexpressed in ESCC. Using a patient-derived xenograft (PDX) mouse model of ESCC, animals were randomized into four groups: control, anti-PD-1 monotherapy, CAR-T monotherapy, and combination therapy. Tumor growth was monitored, and tumors were analyzed by flow cytometry for immune cell infiltration, multiplex immunofluorescence for spatial distribution of T cells and PD-L1 expression, and RNA sequencing to identify altered signaling pathways. The combination therapy group showed superior tumor suppression compared to all other groups (p<0.001). Flow cytometry revealed a 2.5-fold increase in tumor-infiltrating CAR-T cells and a significant reduction in regulatory T cells and myeloid-derived suppressor cells in the combination group. Spatial analysis confirmed enhanced CAR-T cell penetration and decreased PD-L1+ immunosuppressive niches. RNA-seq indicated upregulation of interferon-gamma and T cell receptor signaling pathways and downregulation of TGF-β-mediated immunosuppression in the combination therapy group. Combining mesothelin-targeted CAR-T cells with PD-1 blockade effectively reprograms the immunosuppressive TME, enhances CAR-T cell infiltration and function, and achieves significantly greater anti-tumor activity in ESCC. This combination strategy represents a promising translational approach to improve CAR-T cell efficacy in solid tumors.

Ning Zhao · Diseases of the esophagus · 0 citations